AR087501A1 - Compuestos inhibidores del canal ionico del potencial receptor transitorio trpa1 - Google Patents

Compuestos inhibidores del canal ionico del potencial receptor transitorio trpa1

Info

Publication number
AR087501A1
AR087501A1 ARP120102918A ARP120102918A AR087501A1 AR 087501 A1 AR087501 A1 AR 087501A1 AR P120102918 A ARP120102918 A AR P120102918A AR P120102918 A ARP120102918 A AR P120102918A AR 087501 A1 AR087501 A1 AR 087501A1
Authority
AR
Argentina
Prior art keywords
trpa1
receiver
inhibiting compounds
ionic channel
potential transitory
Prior art date
Application number
ARP120102918A
Other languages
English (en)
Inventor
Yugui Gu
Spencer D Kimball
Qingy Li
Blaise S Lippa
Dominic Ryan
Xinyuan Wu
Dong ZOU
Chester A Metcalf Iii
Original Assignee
Hydra Biosciences Inc
Cubist Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hydra Biosciences Inc, Cubist Pharm Inc filed Critical Hydra Biosciences Inc
Publication of AR087501A1 publication Critical patent/AR087501A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Esta divulgación describe un compuesto de fórmula (1) (por ejemplo, fórmula (1a)) y composiciones farmacéuticas para inhibir el canal iónico TRPA1 y/o afecciones médicas relacionadas con TRPA1, tal como el dolor.Reivindicación 1: Un compuesto de fórmula (1), o una de sus sales farmacéuticamente aceptables.
ARP120102918A 2011-08-09 2012-08-09 Compuestos inhibidores del canal ionico del potencial receptor transitorio trpa1 AR087501A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161521705P 2011-08-09 2011-08-09

Publications (1)

Publication Number Publication Date
AR087501A1 true AR087501A1 (es) 2014-03-26

Family

ID=46717941

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102918A AR087501A1 (es) 2011-08-09 2012-08-09 Compuestos inhibidores del canal ionico del potencial receptor transitorio trpa1

Country Status (13)

Country Link
US (1) US9193729B2 (es)
EP (1) EP2742048B1 (es)
JP (1) JP2014521724A (es)
KR (1) KR20140073496A (es)
CN (1) CN103265543A (es)
AR (1) AR087501A1 (es)
AU (1) AU2012294300A1 (es)
BR (1) BR112014002960A2 (es)
CA (1) CA2843965A1 (es)
MX (1) MX2014001551A (es)
RU (1) RU2014108885A (es)
TW (1) TW201311690A (es)
WO (1) WO2013023102A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012294300A1 (en) 2011-08-09 2014-03-20 Hydra Biosciences, Inc. Inhibiting transient receptor potential ion channel TRPA1
CN104203236A (zh) 2012-01-17 2014-12-10 味之素株式会社 杂环酰胺衍生物和含有其的药物
US20140163048A1 (en) * 2012-08-09 2014-06-12 Cubist Pharmaceuticals, Inc. Compositions with increased stability for inhibiting transient receptor potential ion channel trpa1
US9394308B2 (en) 2013-01-18 2016-07-19 Merck Sharp & Dohme Corp. Inhibiting the transient receptor potential A1 ion channel
TW201441225A (zh) 2013-01-18 2014-11-01 Cubist Pharm Inc 瞬時受體電位ａ１離子通道之抑制
CA2899646C (en) 2013-03-15 2021-08-31 Hydra Biosciences, Inc. Substituted xanthines and methods of use thereof
GB201309333D0 (en) 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators
TWI676626B (zh) * 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位ａ１離子通道
ES2788395T3 (es) 2014-09-19 2020-10-21 Lilly Co Eli Inhibición del canal iónico del receptor de potencial transitorio A1
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
EP3554500A1 (en) 2016-12-16 2019-10-23 Galderma Research & Development Trpa1 antagonists for use in the treatment of atopic dermatitis
BR112020014584A2 (pt) * 2018-01-31 2020-12-01 Eli Lilly And Company inibição do canal iônico do receptor de potencial transitório a1
IT202100015098A1 (it) 2021-06-09 2022-12-09 Flonext S R L Composto antagonista del canale trpa1 per uso in patologie degenerative della retina
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1708703A4 (en) 2003-12-11 2008-04-09 Anormed Inc CHEMOKIN RECEPTOR BINDING COMPOUNDS
WO2005065050A2 (ja) 2003-12-25 2005-07-21 Asahi Kasei Pharma Corporation ２環化合物
WO2007002933A2 (en) 2005-06-28 2007-01-04 Stout Medical Group, Inc. Micro-thin film structures for cardiovascular indications
DE102005054610B4 (de) 2005-11-08 2010-06-10 Awd.Pharma Gmbh & Co. Kg Flupirtin enthaltende Arzneimittelzubereitung mit kontrollierter Wirkstofffreisetzung
JP5858557B2 (ja) * 2005-12-22 2016-02-10 ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 疼痛を処置するためのｔｒｐａ１阻害剤
JP2010530901A (ja) * 2007-06-22 2010-09-16 ハイドラ バイオサイエンシズ インコーポレイテッド 障害を治療するための方法および組成物
WO2009144548A1 (en) 2008-05-28 2009-12-03 Glenmark Pharmaceuticals S.A. Imidazo [2,1-b] purine derivatives as trpa1 modulators
WO2009152261A1 (en) 2008-06-10 2009-12-17 Brandeis University Methods of insect control by inhibiting or modulating the trpa1 ion gated channel or family members
WO2010004390A1 (en) 2008-06-17 2010-01-14 Glenmark Pharmaceuticals, S.A. Quinazoline dione derivatives as trpa1 modulators
WO2010075353A1 (en) * 2008-12-22 2010-07-01 Hydra Biosciences, Inc. Compositions useful for treating disorders related to trpa1
AP3280A (en) 2009-03-23 2015-05-31 Glenmark Pharmaceuticals Sa Fused pyrimidine-dione derivatives as TRPA1 modulators
WO2010138879A1 (en) * 2009-05-29 2010-12-02 Hydra Biosciences, Inc. Compounds useful for treating disorders related to trpa1
WO2010141805A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heterocyclic amides as modulators of trpa1
WO2011043954A1 (en) 2009-10-07 2011-04-14 Merck Sharp & Dohme Corp. Novel trpa1 antagonists
WO2011114184A1 (en) 2010-03-15 2011-09-22 Glenmark Pharmaceuticals S.A. Amides of heterocyclic compounds as trpa1 inhibitors
JP5847827B2 (ja) 2010-10-12 2016-01-27 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｔｒｐａ１受容体アンタゴニスト
JP5694560B2 (ja) 2010-12-20 2015-04-01 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐａ１アンタゴニストとしての２−アミノ−４−アリールチアゾール化合物
JP2014517031A (ja) 2011-06-13 2014-07-17 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐａ１アンタゴニストを使用した呼吸器疾患の治療
AU2012294300A1 (en) 2011-08-09 2014-03-20 Hydra Biosciences, Inc. Inhibiting transient receptor potential ion channel TRPA1
US20140158116A1 (en) 2012-08-09 2014-06-12 Cubist Pharmaceuticals, Inc. Inhibiting trpa1 for the treatment of asthma
US20140163048A1 (en) 2012-08-09 2014-06-12 Cubist Pharmaceuticals, Inc. Compositions with increased stability for inhibiting transient receptor potential ion channel trpa1
US9394308B2 (en) 2013-01-18 2016-07-19 Merck Sharp & Dohme Corp. Inhibiting the transient receptor potential A1 ion channel
TW201441225A (zh) 2013-01-18 2014-11-01 Cubist Pharm Inc 瞬時受體電位ａ１離子通道之抑制

Also Published As

Publication number Publication date
TW201311690A (zh) 2013-03-16
CN103265543A (zh) 2013-08-28
RU2014108885A (ru) 2015-09-20
US20130274273A1 (en) 2013-10-17
WO2013023102A1 (en) 2013-02-14
EP2742048A1 (en) 2014-06-18
EP2742048B1 (en) 2016-04-27
KR20140073496A (ko) 2014-06-16
JP2014521724A (ja) 2014-08-28
CA2843965A1 (en) 2013-02-14
AU2012294300A1 (en) 2014-03-20
BR112014002960A2 (pt) 2017-02-21
US9193729B2 (en) 2015-11-24
MX2014001551A (es) 2014-09-15

Similar Documents

Publication Publication Date Title
AR087501A1 (es) Compuestos inhibidores del canal ionico del potencial receptor transitorio trpa1
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
CR20150371A (es) Inhibidores de prmt5 y sus usos
MX2015012427A (es) Compuestos de morfolinona de acido heteroarilo como inhibidores mdm2 para el tratamiento de cancer.
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
MX383686B (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
MX380394B (es) Compuesto novedoso de bifenilo o una sal del mismo.
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
MX336497B (es) Compuestos de tetrahidro-pirido-piridina y tetrahidro-pirido-pirim idina y su uso como moduladores de los receptores de c5a.
NZ716840A (en) Combination formulation of two antiviral compounds
TN2015000391A1 (en) Compounds and compositions for the treatment of parasitic diseases
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
MX379300B (es) Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales.
MX351816B (es) Formulacion de combinacion de dos compuestos antivirales.
CY1118478T1 (el) Παραγωγα τυπου αζαϊνδαζολιου ή διαζαϊνδαζολιου για τη θεραπεια του πονου
CO6690768A2 (es) Derivados de triazina-oxadiazoles, útiles como inhibidores de los canales de sodio navi.7
MY187718A (en) Pharmaceutical formulations
MX2015005735A (es) Moduladores de dihidropirazol de receptor acoplado a la proteona g (gpr40).
MX2015005858A (es) Moduladores del receptor acoplado a proteina g (gpr40) de dihidropirazol.
MX2015005720A (es) Moduladores de dihidropirazol de receptor acoplado a la proteina g (gpr40).
ECSP13012600A (es) CO-cristales y Sales de Inhibidores de CCR3
UY35359A (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS SUSTITUIDAS Y MÉTODOS DE USO
CR20150325A (es) Compuestos trcíclicos para inhibir el canal cftr
MX362879B (es) Usos novedosos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure